Inteligencia Artificial en el desarrollo de fármacos:

Jorge Arturo  Hernández Valencia; Martiniano  Bello Ramírez

Jorge Arturo Hernández Valencia Laboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica Escuela Superior de Medicina del Instituto Politécnico Nacional
Martiniano Bello Ramírez Laboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica Escuela Superior de Medicina del Instituto Politécnico Nacional

Keywords: Artificial Intelligence, Drug development, ethics, data analysis

Abstract

Drug development is a lengthy process involving high costs and a high failure rate. Currently, the most widely used method is one based on experience and scientific literature. However, there is a large amount of healthcare data, but most of it is fragmented or isolated, and incorporating it could increase the success rates of clinical trials. Artificial Intelligence (AI) can accelerate this process with its ability to quickly analyze and integrate large amounts of data, delivering more accurate results. Furthermore, it is essential to address ethical and legal considerations when incorporating AI technologies into clinical trials. To this end, policies and safety measures are emerging for their responsible use in medical attention and to ensure safe and effective implementation.

Downloads

Download data is not yet available.

References

Anuyah, S., K Singh, M., Nyavor, H. (2024). Advancing clinical trial outcomes using deep learning and predictive modelling: bridging precision medicine and patient-centered care. World Journal of Advanced Research and Reviews, 24(03), 001–025. https://doi.org/10.30574/wjarr.2024.24.3.3671

Badal, K., Lee, C. M., & Esserman, L. J. (2023). Guiding principles for the responsible development of artificial intelligence tools for healthcare. Commun Med (Lond), 3(1), 47. https://doi.org/10.1038/s43856-023-00279-9

Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A., & Garcia-Fandino, R. (2023). The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals (Basel), 16(6). https://doi.org/10.3390/ph16060891

FDA (2024). “Novel Drug Approvals for 2024”. Recuperado el 15 de mayo de 2025, de https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024

Idnay, B., Butler, A., Fang, et al. (2023). Principal Investigators' Perceptions on Factors Associated with Successful Recruitment in Clinical Trials. AMIA Jt Summits Transl Sci Proc, 2023, 281-290.

Mullard, A. (2020). $1.3 billion per drug? Nat Rev Drug Discov, 19(4), 226. https://doi.org/10.1038/d41573-020-00043-x

Naik, N., Hameed, B. M. Z., et al. (2022). Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility? Front Surg, 9, 862322. https://doi.org/10.3389/fsurg.2022.862322

NCI (2024). NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients. Recuperado el 20 de mayo de 2025, de https://www.cancer.gov/news-events/press-releases/2024/ai-tool-matches-cancer-drugs-to-patients

Sinha, S., Vegesna, R., et al. (2024). PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nat Cancer, 5(6), 938-952. https://doi.org/10.1038/s43018-024-00756-7

Zhao, X., Iqbal, S., Valdes, I. L., Dresser, M., & Girish, S. (2022). Integrating real-world data to accelerate and guide drug development: A clinical pharmacology perspective. Clin Transl Sci, 15(10), 2293-2302. https://doi.org/10.1111/cts.13379

Inteligencia Artificial en el desarrollo de fármacos

retos y oportunidades para su uso responsable

Abstract

Downloads

References